Literature DB >> 9633719

Global cerebral blood flow, blood volume, and oxygen metabolism in patients with migraine headache.

E M Bednarczyk1, B Remler, C Weikart, A D Nelson, R C Reed.   

Abstract

OBJECTIVE: Migraine headaches with and without aura are representative of vascular headache states traditionally thought to be mediated by alterations in vascular tone. Validation of this theory has been hampered in part by technical difficulties inherent in the measurement of cerebral blood flow (CBF). The purpose of this study was to compare CBF measured during migraine and migraine-free states using PET.
METHODS: Patients with a minimum of one migraine headache without aura per month (International Headache Society [IHS] criteria) underwent measurement of CBF, cerebral blood volume (CBV), oxygen extraction, and metabolism during an episode of spontaneous migraine headache. Imaging was repeated during a migraine-free period of at least 48 hours. PET radiotracers used were: CBF, H(2)15O; CBV, C15O; oxygen metabolism, 15O2.
RESULTS: In nine patients (seven female and two male), global CBF (mL/min/100 g [SD]) was measured as 52.70 (6.9) during migraine and 59.65 (10.6) in the migraine-free state; p=0.028. CBV (mL/100 g [SD]) was 3.6 (0.43) during the symptomatic state and 3.8 (0.55) after the migraine; p=0.047. Oxygen metabolism (mL/min/100 g [SD]) was 3.68 (0.9) during migraine and 3.38 (1.02) without headache; p=0.211. The oxygen extraction ratio was 0.48 (0.15) and 0.41 (0.12) during migraine and migraine-free states, respectively; p=0.132.
CONCLUSIONS: In patients experiencing migraine without aura, CBF and CBV are reduced during the headache phase. Cerebral oxygen metabolism and oxygen extraction are not significantly affected.

Entities:  

Mesh:

Year:  1998        PMID: 9633719     DOI: 10.1212/wnl.50.6.1736

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

1.  Evaluation of cerebellar and cerebral volume in migraine with aura: a stereological study.

Authors:  Ozge Yilmaz-Kusbeci; Nuket Gocmen-Mas; Aylin Yucel; Hamit S Karabekir; Tolga Ertekin; Ayse C Yazici
Journal:  Cerebellum       Date:  2010-09       Impact factor: 3.847

Review 2.  Neuroimaging of migraine.

Authors:  Shazia K Afridi; Peter J Goadsby
Journal:  Curr Pain Headache Rep       Date:  2006-06

Review 3.  Migraine and white matter hyperintensities.

Authors:  Alyx Porter; Jonathan P Gladstone; David W Dodick
Journal:  Curr Pain Headache Rep       Date:  2005-08

4.  A method to enhance the sensitivity of DTI analyses to group differences: a validation study with comparison to voxelwise analyses.

Authors:  Matthew D Cykowski; Jack L Lancaster; Peter T Fox
Journal:  Psychiatry Res       Date:  2011-07-20       Impact factor: 3.222

5.  DTI findings during spontaneous migraine attacks.

Authors:  B Kara; A Kiyat Atamer; L Onat; L Ulusoy; A Mutlu; M Sirvanci
Journal:  Clin Neuroradiol       Date:  2012-08-15       Impact factor: 3.649

Review 6.  Verisimilitude (or "truthlikeness") as an alternative to pro and cons: migraine and cluster headache mechanisms.

Authors:  Peer Carsten Tfelt-Hansen
Journal:  J Headache Pain       Date:  2010-07-07       Impact factor: 7.277

Review 7.  Chronic daily headache.

Authors:  M J Láinez; M J Monzón
Journal:  Curr Neurol Neurosci Rep       Date:  2001-03       Impact factor: 5.081

Review 8.  Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study.

Authors:  M C Kruit; M A van Buchem; L J Launer; G M Terwindt; M D Ferrari
Journal:  Cephalalgia       Date:  2010-02       Impact factor: 6.292

Review 9.  Brain Energy Deficit as a Source of Oxidative Stress in Migraine: A Molecular Basis for Migraine Susceptibility.

Authors:  Jonathan M Borkum
Journal:  Neurochem Res       Date:  2021-04-30       Impact factor: 3.996

Review 10.  Cerebral hemodynamics in the different phases of migraine and cluster headache.

Authors:  Jakob M Hansen; Christoph J Schankin
Journal:  J Cereb Blood Flow Metab       Date:  2017-08-31       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.